مؤتمر
237 InnovaTV 301/ENGOT-Cx12/GOG-3057: a global, randomized, open-label, phase 3 study of tisotumab vedotin versus investigator’s choice of chemotherapy in 2L Or 3L recurrent or metastatic cervical cancer
العنوان: | 237 InnovaTV 301/ENGOT-Cx12/GOG-3057: a global, randomized, open-label, phase 3 study of tisotumab vedotin versus investigator’s choice of chemotherapy in 2L Or 3L recurrent or metastatic cervical cancer |
---|---|
المؤلفون: | Martín, Antonio Gonzalez, Slomovitz, Brian M, Fujiwara, Keiichi, Kalbacher, Elsa, Bagameri, Andrea, Ghamande, Sharad, Lee, Jung-Yun, Banerjee, Susana, Maluf, Fernando, Lorusso, Domenica, Yonemori, Kan, Nieuwenhuysen, Els Van, Sánchez, Luis Manso, Woelber, Linn, Westermann, Anneke, Covens, Allan, Whalley, Elizabeth, Leng Teng, Melinda Siew, Soumaoro, Ibrahima, Vergote, Ignace |
المصدر: | Oral Sessions |
بيانات النشر: | BMJ Publishing Group Ltd |
سنة النشر: | 2024 |
نوع الوثيقة: | conference object |
اللغة: | unknown |
DOI: | 10.1136/ijgc-2024-esgo.7 |
DOI: | 10.1136/ijgc-2024-ESGO.7 |
الإتاحة: | https://doi.org/10.1136/ijgc-2024-esgo.7Test |
رقم الانضمام: | edsbas.9C9C4259 |
قاعدة البيانات: | BASE |